Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17048784 | 0.82 | CNR1 (0.40) | CNR1MAPTLMNAGAAALDH1A1 | |
| SCHEMBL8634074 | 0.80 | AOC3 (0.44) | AOC3GAAHTR6 | |
| SCHEMBL4886452 | 0.80 | AOC3 (0.44) | AOC3GAAHTR6 | |
| SCHEMBL5009193 | 0.80 | AOC3 (0.48) | AOC3GAAHTR6 | |
| SCHEMBL8986918 | 0.80 | AOC3 (0.44) | AOC3GAAHTR6 | |
| SCHEMBL17048974 | 0.76 | ALDH1A1 (0.33) | CNR1MAPTMEN1KMT2AGAA | |
| SCHEMBL17048774 | 0.75 | NPSR1 (0.38) | CNR1MAPTLMNAALDH1A1TDP1 | |
| SCHEMBL13986540 | 0.75 | CNR1 (0.48) | CNR1AOC3MAPTMEN1KMT2A | |
| SCHEMBL16321684 | 0.75 | CNR1 (0.48) | CNR1AOC3MAPTMEN1KMT2A | |
| SCHEMBL17048806 | 0.75 | S1PR4 (0.33) | CNR1MAPTLMNAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470696-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470696-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470713-B2 | Imidazole based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470713-B2 | Imidazole based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1381598-A4 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1581539-A4 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-09-19 | — | — | EP | disclosed |
| US-7232826-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232826-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-19 | — | — | US | disclosed |
| US-20070135443-A1 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135443-A1 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| EP-1545543-A2 | NOVEL TYROSINE KINASES INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-1545529-A2 | NOVEL TYROSINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040180897-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
| WO-2004063151-A2 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040092514-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-13 | — | — | US | disclosed |
| WO-2004030620-A2 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031401-A2 | NOVEL TYROSINE KINASES INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-04 | — | — | US | disclosed |
| EP-1381598-A1 | NOVEL TYROSINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-01-21 | — | — | EP | disclosed |
| WO-2002079192-A1 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180897-A1 | Novel tyrosine kinase inhibitors | ABL1, ROS1, YES1 | CNR1 4183/4885AOC3 3360/4885MAPT 4438/4885 |
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | ABL1, YES1, FER | CNR1 4361/4885AOC3 2411/4885MAPT 4113/4885 |
| US-20040092514-A1 | Novel tyrosine kinase inhibitors | ABL1, ERBB2, ROS1 | CNR1 4148/4885AOC3 2850/4885MAPT 4085/4885 |
| US-20070135443-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, ERBB2, ROS1 | CNR1 4414/4885AOC3 3298/4885MAPT 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.